216 related articles for article (PubMed ID: 17118476)
1. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
Okuda T; Kawakami S; Akimoto N; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Dec; 116(3):330-6. PubMed ID: 17118476
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration.
Okuda T; Kawakami S; Maeie T; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Aug; 114(1):69-77. PubMed ID: 16814896
[TBL] [Abstract][Full Text] [Related]
3. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
5. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
6. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
7. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
8. Methoxypoly(ethylene glycol)-conjugated carboxypeptidase A for solid tumor targeting: part II: pharmacokinetics and biodistribution in normal and tumor-bearing rodents.
Ton GN; Weichert JP; Longino MA; Fine JP; Kwon GS
J Control Release; 2005 May; 104(1):155-66. PubMed ID: 15866342
[TBL] [Abstract][Full Text] [Related]
9. The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers.
Lim J; Guo Y; Rostollan CL; Stanfield J; Hsieh JT; Sun X; Simanek EE
Mol Pharm; 2008; 5(4):540-7. PubMed ID: 18672950
[TBL] [Abstract][Full Text] [Related]
10. PEGylated dendrimers with core functionality for biological applications.
Guillaudeu SJ; Fox ME; Haidar YM; Dy EE; Szoka FC; Fréchet JM
Bioconjug Chem; 2008 Feb; 19(2):461-9. PubMed ID: 18173227
[TBL] [Abstract][Full Text] [Related]
11. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
12. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
Singh P; Gupta U; Asthana A; Jain NK
Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biodistribution, and microsingle photon emission computed tomography (SPECT) imaging study of technetium-99m labeled PEGylated dendrimer poly(amidoamine) (PAMAM)-folic acid conjugates.
Zhang Y; Sun Y; Xu X; Zhang X; Zhu H; Huang L; Qi Y; Shen YM
J Med Chem; 2010 Apr; 53(8):3262-72. PubMed ID: 20350006
[TBL] [Abstract][Full Text] [Related]
14. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
15. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
Boyd BJ; Kaminskas LM; Karellas P; Krippner G; Lessene R; Porter CJ
Mol Pharm; 2006; 3(5):614-27. PubMed ID: 17009860
[TBL] [Abstract][Full Text] [Related]
16. Targeting the lymphatics using dendritic polymers (dendrimers).
Kaminskas LM; Porter CJ
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):890-900. PubMed ID: 21683746
[TBL] [Abstract][Full Text] [Related]
17. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
18. Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.
Kaminskas LM; Wu Z; Barlow N; Krippner GY; Boyd BJ; Porter CJ
J Pharm Sci; 2009 Oct; 98(10):3871-5. PubMed ID: 19283758
[TBL] [Abstract][Full Text] [Related]
19. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
DeNardo SJ; Yao Z; Lam KS; Song A; Burke PA; Mirick GR; Lamborn KR; O'Donnell RT; DeNardo GL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3854S-64S. PubMed ID: 14506183
[TBL] [Abstract][Full Text] [Related]
20. Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration.
de Wolf HK; Snel CJ; Verbaan FJ; Schiffelers RM; Hennink WE; Storm G
Int J Pharm; 2007 Mar; 331(2):167-75. PubMed ID: 17134859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
